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NRF2-driven miR-125B1 and miR-29B1 transcriptional
regulation controls a novel anti-apoptotic miRNA
regulatory network for AML survival
NM Shah1,2, L Zaitseva1, KM Bowles1,3, DJ MacEwan2,4 and SA Rushworth*,1,4
Transcription factor NRF2 is an important regulator of oxidative stress. It is involved in cancer progression, and has abnormal
constitutive expression in acute myeloid leukaemia (AML). Posttranscriptional regulation by microRNAs (miRNAs) can affect the
malignant phenotype of AML cells. In this study, we identified and characterised NRF2-regulated miRNAs in AML. An miRNA array
identified miRNA expression level changes in response to NRF2 knockdown in AML cells. Further analysis of miRNAs
concomitantly regulated by knockdown of the NRF2 inhibitor KEAP1 revealed the major candidate NRF2-mediated miRNAs in AML.
We identified miR-125B to be upregulated and miR-29B to be downregulated by NRF2 in AML. Subsequent bioinformatic analysis
identified putative NRF2 binding sites upstream of the miR-125B1 coding region and downstream of the mir-29B1 coding region.
Chromatin immunoprecipitation analyses showed that NRF2 binds to these antioxidant response elements (AREs) located in the
5′ untranslated regions of miR-125B and miR-29B. Finally, primary AML samples transfected with anti-miR-125B antagomiR or
miR-29B mimic showed increased cell death responsiveness either alone or co-treated with standard AML chemotherapy.
In summary, we find that NRF2 regulation of miR-125B and miR-29B acts to promote leukaemic cell survival, and their manipulation
enhances AML responsiveness towards cytotoxic chemotherapeutics.
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Acutemyeloid leukaemia (AML) is a biologically heterogenous
disorder that occurs as a consequence of a wide variety of
genetic abnormalities in haematopoietic progenitors that are
derived from the bone marrow.1 However, it is likely that AML
share various survival pathways downstream of the driver
mutations, making the existence of common survival path-
ways and therapeutic targets likely.2
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a
member of the Cap ‘n’Collar basic leucine zipper transcription
factor family that protects cells from reactive oxygen species
through the regulation of a number of cytoprotective genes
including heme oxygenase-1 (HO-1) and NAD(P)H dehydro-
genase quinone 1 (NQO1).3–5 In cancer, NRF2 activation is
pro-tumoural in a spectrum of malignancies throughmutations
in NRF2 or its cytosolic inhibitor KEAP1.6–9 However, we have
previously shown that in human AML constitutive activation of
the NRF2 signalling pathway is not through somatic mutations
of NRF2/Keap1 but as a consequence of upstream constitu-
tive activation by NF-κB.10,11 In addition to contributing to the
malignant phenotype of AML, we also found that NRF2
contributes to intrinsic leukaemia cell resistance to standard
front-line chemotherapy agents.12,10
microRNAs (miRNAs) are short non-coding RNA mole-
cules, approximately 20–30 nucleotides in length, that can
posttranscriptionally regulate gene expression by binding to
the 3′ UTR of their target mRNA, thereby repressing gene
transcription.13 miRNA expression has shown to be dysregu-
lated in a range of cancers, and can act as tumour suppressor
miRs (by downregulating oncogenes) or oncomiRs (by
targeting tumour suppressors).14 miRNAs are being increas-
ingly studied with the expectation that modulation of their
expression can be harnessed to improve cancer therapy. A
recent study using chromatin immunoprecipitation sequen-
cing (ChIP-Seq) identified high-confidence ChIP-Seq peaks
for NRF2 binding in the vicinity of several miRNAs, suggesting
they could be regulated by NRF2.15
In the present study, we look to identify whether NRF2
regulates miRNA in human AML. Furthermore, we evaluate
whether NRF2-regulated miRNAs have functional importance
not only on the biology of the disease but also in the leukaemia
cell death to chemotherapy treatment.
Results
Lentiviral NRF2 knockdown alters miRNA expression.
NRF2 can regulate drug resistance in AML via the induction
of cytoprotective and detoxification genes.10,12 To assess
whether NRF2 regulates miRNA expression in AML, we used
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a commercially available OncomiR Cancer miRNA qRT-PCR
Array on THP-1 cells infected with an NRF2 lentiviral
knockdown (NRF2-KD) and a negative control knockdown
(NEG-KD). Figure 1a shows the change in expression of
miRNA in response to NRF2-KD compared with the control
infected with NEG-KD. We then treated THP-1 cells with the
NRF2 activator sulforaphane for 6 h for comparison.
Supplementary Table 1 shows the fold increase of miRNA
in response to both NRF-KD and sulforaphane treatment.
From these experiments, we identified miR-125B, miR-222,
miR-221 and miR-223 as potential miRNAs upregulated by
NRF2 and miR-29B and miR-154 as potential miRNAs
downregulated by NRF2. Figure 1c shows western blot
analysis of NRF2 and KEAP1 protein expression in THP-1
cells in response to NRF2-KD, KEAP1-KD and NEG-KD.
Increased NRF2 activity increases miR-125B and
decreases miR-29B expression in AML. We used a qRT-
PCR approach to validate the data from the lentiviral array
experiments.10 NRF2-KD results in THP-1 cells showing a
consistent decrease in miR-125B expression and increasing
miR-29B expression as well as smaller but not significant
fluctuations in miR-221, miR-222, miR-223 and miR-154
expression (Figure 1b). To further assess the role of NRF2 in
regulating miRNA, we increased the activity of NRF2 in
THP-1 cells by knockdown of the NRF2 inhibitor KEAP1.16
THP-1 were infected with KEAP1 lentiviral knockdown
(KEAP1-KD). QRT-PCR confirmed the downregulation of
KEAP1 and as a positive control, we showed that KEAP-KD
upregulated the NRF2 target gene HO-1. Moreover,
miR-125B expression showed a similar increase to HO-1
and miR-29B showed a significant decrease in response to
KEAP1-KD (Figure 1b). The expression of miR-221, miR-
-222, miR223 and miR-154 were not significantly changed in
response in NRF2-KD or KEAP1-KD to warrant its inclusion
in further experiments.
NRF2 regulates homologues miR-125B1 and miR-29B1
and miR-29A in human AML. Both miR-125B and miR-29B
exist as two homologues (Figure 2a). miR-125B1 (located on
chromosome 11) and miR-125B2 (located on chromosome
21), both contain identical seed sequences. Both homo-
logues lie in the region of regulatory miRNA clusters,
miR-100-let-7-a-2 and LINC00478, respectively. miR-29B
also exists as two homologues, miR-29B1 (located on
chromosome 7) and miR-29B2 (located on chromosome 1)
(Figure 2a).
The sequence of themiRNA seed region of bothmiR-125B1
and 2 is identical. Similarly, the seed sequence of miR-29B1 is
identical to that of miR-29B2. Therefore, we used primers
designed specifically for the immature miRNA sequences
(which does differ between themiRNA homologues) to identify
which miR-125B and miR-29B homologues were being
regulated by NRF2. QRT-PCR on lentiviral NRF2-KD THP-1
cells identified reduced expression of the immature
miR-125B1 and increased expression of the immature miR-
-29B1, but no change in the expression of immature
miR-125B2 and miR-29B2 sequence (Figures 2b and c). This
suggests that miR-125B1 and miR-29B1, but not miR-125B2
or miR-29B2, are regulated by NRF2.
To determine whether NRF2 specifically regulated
miR-125B1 and miR-29B1 or had a more general regulatory
effect on their clusters, we looked for a differential expression
on other miRNAs in each of the homologue regions in
response to NRF2-KD. Following NRF2 knockdown, however,
there was no difference in the expression of miR-100 and
let-7a-2 (miR-125B1 cluster; chromosome 11) or miR-99a and
let7c (miR-125B2 cluster; chromosome 21) (Figure 2b). This
implies that NRF2 does not regulate these clusters to control
miR-125B expression but instead binds to a miR-125B1-
specific regulatory region. Conversely, knockdown of NRF2
elevated miR-29B1 and miR-29A but had no effect on
miR-29B2 andmiR-29C (Figure 2c). NRF2 therefore regulates
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Figure 1 miRNA profiling of AML cells in response lentiviral NRF2 knockdown. (a) THP-1 cells were transduced with NEG (NEG-KD)- and NRF2 (NRF2-KD)-targeted miRNA
lentiviral constructs. QRT-PCR analysis of 92 cancer-associated miRNAs in NRF2-KD THP-1 cells. Values represent change in qRT-PCR cycle threshold normalised to RNU6B
(ΔCT). Dashed line indicates no change in expression. A red circle indicates miR-125B, miR221, miR-223, miR222, miR29B and miR154. (b) QRT-PCR of miR-125B, miR221,
miR-223, miR222, miR29B, miR154, NRF2, KEAP1 and HO1 in THP-1 cells transduced with NEG-KD, NRF2-KD or KEAP1-KD. Values represent fold change in RNA expression
over NEG-KD control. (c) THP-1 were transduced with NEG-KD, NRF2-KD or KEAP1-KD before cells were analysed for NRF2 and KEAP1 using western blotting. Blots were
reprobed for β-actin to show sample loading. The numbers under the blots indicate densitometry analysis of the blots using Image J software, and the results are expressed as
fold change relative to the NEG-KD control
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a defined pattern of expression of the miR-125B1 and
miR-29B1 cluster in human AML. Moreover, results from
Figure 1b and Figures 2b and c show that changes in total
levels of miR-125B and miR-29B are similar to changes in
miR-125B1 and miR-29B1. The main reason for this similarity
is that constitutive levels of miR-125B2 and miR-29B2 are
much lower in AML than that of their homologue, thus changes
observed in total miR-125B and miR-29B reflect changes
observed in miR-125B1 and miR-29B1 levels.
NRF2 binds to ARE sites in the promoters of miR-125B1
and miR-29B1. NRF2 acts as a transcription factor by
binding to the antioxidant response element (ARE) region in
the promoter regions of its target genes.17 To analyse the
5′ miR-125B1 and miR-29B1 promoter sequence, we used
transcription factor analysis programmes (http://www.gene-
regulation.com/cgi-bin/pub/programs/pmatch/bin/p-match.cgi
and www.genomatix.de/matinspector.html). These analyses
identified three potential ARE sites within the miR-125B1
promoter and two in the miR-29B1 promoter (Figure 3a).
To confirm whether NRF2 bound to ARE binding sites in the
miR-29B1 or the miR-125B1 promoter, a ChIP assay was
undertaken. Figure 3b shows the analysis using antibodies for
NRF2 and quantified against control IgG with specific primers
for ARE1-3 (promoter region of miR-125B1; chromosome 11)
and ARE4 and ARE5 (promoter region of miR-29B1; chromo-
some 7). Recruitment of NRF2 was markedly enhanced to
ARE5 in the miR-29B1 promoter and ARE3 in the miR-125B1
promoter. Next, we evaluated the recruitment of NRF2 to
ARE1-5 sites in THP-1 cells transfected with KEAP1 siRNA.
Figure 3c shows that there was increased recruitment of NRF2
to the ARE3 and ARE5 site, but not the other potential ARE
sites in THP-1 cells transfected with KEAP siRNA over control
siRNA. These observations confirmed that NRF2 specifically
binds the miR-29B1 ARE5 site and the miR-125B1 ARE3 site.
To establish whether NRF2 functionally controls miR-125B1
expression, the miR-125B1 promoter was cloned into a PGL4
luciferase plasmid and the putative ARE3 site was mutated
(Figure 3d). AML is a disease characterised by constitutive
activation of NRF2, therefore the luciferase vector PGL4 and
PGL4/p125B were transfected into THP-1 cells without prior
treatment of an NRF2 activator or repressor. We observed an
approximate eightfold increase in luciferase activity in the
PGL4/p125B plasmid in comparison with the control
(Figure 3e). Site-directed mutagenesis of the ARE3 site in
the miR-125B1 promoter corresponded with a significant
decrease in miR-125B1 promoter activity (Figure 3e). More-
over, when we co-transfected KEAP1 and NRF2 siRNA with
the p125B and p125BNRF2Mut plasmids, KEAP1 siRNA
induced significant increase in p125B promoter activity and
NRF2 siRNA inhibited p125B promoter activity. KEAP1 siRNA
and NRF2 siRNA had no effect on p125BNRF2Mut promoter
activity (Figure 3f). Similar experiments on the miR-29B1
promoter were technically not possible as the construct was
too big and would not clone into a luciferase reporter vector.
These results demonstrate that the ARE3 site in the promoter
of mir-125B1 is regulated by NRF2.
NRF2 regulates the expression of miR-125B1 and
miR-29B1 in primary human AML. As we have established
in AML that high NRF2 mRNA expression causes an
increase in NRF2 activity,10 and that miR-125B1 and
miR-29B1 are regulated by NRF2 in AML cell lines, we next
examined the expression of NRF2, mir-125B1 and miR-29B1
in primary human AML cells. NRF2 and miR-125B1 is
increased in AML compared with normal CD34+ haemato-
poietic stem cells (HSC), whereas miR-29B1 is decreased in
AML compared with normal CD34+ HSC (Figure 4a). As total
levels of miR-125B and miR-29B most likely determine their
biological function, we analysed total levels of miR-125B and
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Figure 2 NRF2 regulates homologues miR-125B1 and miR-29B1 and miR-29A in human AML. (a) Schematic representation of the miRNA chromosomal positioning of
miR-125B (1 and 2) and miR-29B (1 and 2). (b) Total RNA was extracted from THP-1 transduced with NEG-KD and NRF2-KD and examined for miRNA expression including
immature miR-125B1, miR-125B2 RNA and HO-1 mRNA expression. (c) Total RNA was extracted from THP-1 transduced with NEG-KD and NRF2-KD and examined for
miR-29A and miR-29C expression including immature miR-29B1, miR-29B2 RNA and HO-1 mRNA expression
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miR-29B in AML. Supplementary Figure 2 shows that total
miR-125B is increased in AML compared with normal CD34+
HSC, whereas miR-29B is decreased in AML compared
with normal CD34+ HSC. Furthermore, there is a positive
correlation between NRF2 RNA expression and mir-125B1
RNA expression, with an inverse correlation between NRF2
RNA expression and miR-29B1 RNA expression in primary
AML cells (Figure 4b). To confirm that NRF2 regulates
miR-125B1 and miR-29B1 expression in primary human AML
cells, we used NRF2 siRNA to silence NRF2 RNA expression
in eight AML patient samples. NRF2 mRNA is significantly
knocked down in seven out of the eight AML samples of
which the majority also had significantly lower miR-125B1
expression (Figure 4c). Moreover, NRF2 siRNA in the AML
samples increased miR-29B1 expression (Figure 4c).
Together, these results show that knockdown of NRF2
regulates the expression of miR-125B1 and miR-29B1 in
primary human AML.
miR-125B antagomiR and miR-29B mimic increases AML
apoptosis and sensitivity to frontline chemotherapy
agents. Previous studies in AML have suggested that the
overexpression of miR-125B plays an oncogenic role by
repressing apoptosis and the reduction of miR-29B increases
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Figure 3 NRF2 binds to ARE sites in the promoters of miR-125B1 and miR-29B1. (a) Schematic presentation of ARE binding sequences in the 5′ region of miR-29B1 on
chromosome 7 and miR-125B1 on chromosome 11. (b) Chromatin immunoprecipitation (ChIP) analysis of the miR-29B1 and miR-125B1 promoter using antibodies against
NRF2 and normal rabbit IgG was used as a control. QRT-PCR was performed in triplicate on immunoprecipitated DNA and input DNA. Data presented as percent of input.
* indicates Po0.05 between the different treatment groups. (c) THP-1 cells were transfected with control siRNA and KEAP1 siRNA for 24 h and ChIP was performed. Real-time
PCR was performed in triplicate on immunoprecipitated DNA and input DNA. Data presented as percent of input. * indicates Po0.05 between the different treatment groups.
(d) Schematic representation of mutated miR-125B promoter sequence. (e) THP-1 cells were transiently transfected with 0.5 μg of each promoter construct including control
plasmid and pRL-TK for normalisation of transfection efficiency. Cell extracts were harvested and luciferase assays were performed. Values are the means± S.D., n= 4.
* indicates Po0.01 of deleted ARE against PGL4 control. (f) Control, KEAP1 and NRF2 siRNAwere transfected at the same time as p125b and p125bNRF2 MUTand incubated
for 48 h. Cell extracts were harvested and luciferase assays were performed. Values are the means±S.D., n= 4. * indicates Po0.01 of KEAP1 siRNA and NRF2 siRNA against
NEG siRNA control
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proliferation and represses apoptosis.18,19 To determine the
functional role of inhibiting miR-125B and overexpressing
miR-29B both alone and in-combination, we transfected
miR-125B antagomiR and miR-29B mimic into THP-1 cells
and analysed cells for apoptosis by annexin V/PI staining.
However, before we did this, we showed that the concentra-
tions of transfected miR-125B antagomiR and miR-29B
mimic used manipulated the miRNA levels comparable with
that observed in the NRF2-KD and KEAP1-KD THP-1 cells
(Supplementary Figure 1). THP-1 cells transfected with the
miR-125B antagomiR or miR-29B mimic showed a small but
significant increase in annexin V/PI staining in comparison
with the control transfection (Figure 5a). Moreover, when we
co-transfected miR-125B antagomir and miR-29B mimic, we
observed a synergistic increase in annexin V/PI staining in
comparison with the control (Figure 5a). Transfection of
miR-125B antagomir and miR29B mimic into THP-1 and
Kasumi-1 cells potentiated the cytotoxic effect of the frontline
AML chemotherapy agent daunorubicin (Supplementary
Table 2).
Next, we examined the effects of inhibiting miR-125B and
increasing miR-29B expression in primary AML cells in
comparison with non-malignant primary CD34+ HSC. In six
primary AML patient samples, inhibition of miR-125B or
increasing miR-29B showed a significant decrease in cell
viability (Figure 5b). Finally, we compared the viability of
primary AML patient cells that had normal NRF2 expression
(and thus normal miR-125B and miR-29B expression) with an
AML patient sample that had high NRF2 expression (and thus
high miR-125B and low miR-29B expression) after treatment
with daunorubicin (Figure 5c and Table 1 and Supplementary
Table 2). AML with normal NRF2 and normal miR-125B and
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Figure 4 NRF2 regulates miR-29B1 and miR-125B1 in primary AML. (a) Total RNA was extracted from patient AML blasts (n= 18) and CD34+ HSC (n= 8). NRF2,
miR-29B1 and miR-125B1 RNA expression levels were measured using QRT-PCR. (b) Pearson’s correlation analysis between miR-125B1 or miR-29B1 and NRF2 mRNA
expression in human primary AML cells. (c) Control and NRF2 siRNA were transfected into primary blasts (n= 7) for 48 h and RNA extracted. RNA was analysed for NRF2,
miR-125B1 and miR-29B RNA expression. Values are the means±S.D., n= 3
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Figure 5 miR-125B antagomiR and miR-29B mimic induce apoptosis of AML cells and increases there sensitivity to AML chemotherapy. (a) THP-1 were transfected with
control miRNA, miR-125B antagomiR (α125B), miR-29B mimic (29B mimic) and miR-125B antagomiR in combination with miR-29B mimic for 48 h before cells were analysed for
apoptosis by PI/Annexin V staining. (b) AML blasts (n= 6) and CD34+ (n= 4) were transfected with control miRNA, miR-125B antagomiR and miR-29B mimic and miR-125B
antagomiR in combination with miR-29B mimic for 24 h and then assessed for cell viability by Cell Titer-GLO. (c) AML blasts and CD34+ cells were transfected with control miRNA
(miR-mimic negative control and the anti-miR miRNA inhibitor negative control for single experiments and combined miR-mimic negative control and the anti-miR miRNA inhibitor
negative control in combined experiments), miR-125B antagomiR, miR-29B mimic and miR-125B antagomiR in combination with miR-29B mimic for 24 h before the addition of
increasing doses of daunorubicin for 48 h. Cells assessed for viability by Cell Titer-GLO. (d) AML#27 was transduced with NEG-KD and KEAP1-KD for 48 h before cells before the
addition of increasing doses of daunorubicin for 48 h before cells were analysed for KEAP1 using western blotting. Blots were reprobed for β-actin to show sample loading.
(e) AML#27 was transduced with NEG-KD and KEAP1-KD for 48 h before the addition of increasing doses of daunorubicin for 48 h. Cells were assessed for viability by Cell
Titer-GLO. (f) AML#27 was transduced with KEAP1-KD for 48 h before cells were transfected with control miRNA, miR-125B antagomiR, miR-29B mimic and miR-125B
antagomiR in combination with miR-29B mimic for 24 h followed by the addition of increasing doses of daunorubicin for 48 h. Cells were assessed for viability by Cell Titer-GLO
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miR-29B expression were much more sensitive to daunor-
ubicin than AML patient samples that had high NRF2
expression and thus high miR-125B and low miR-29B
expression. Moreover, when we transfected the primary AML
that had high NRF2 and high mir-125B and low miR29B with
miR-125B antagomiR together with miR-29B mimic, the result
was that sensitivity of these AML cells to daunorubicin was
increased to a level comparable with AML with normal NRF2
expression. Because AML#27 has low NRF2 expression over
normal CD34+ HSC (Table 1), which is more sensitive to
daunorubicin (Figure 5c), and miR-125B antagomiR together
with miR-29B mimic had no effect on resistance to daunor-
ubicin (Figure 5c), we examined the effect of KEAP1-KD on
AML#27 to determine if we could increase the activity of NRF2
and increase the chemoresistance of this sample. Figure 5d
showsKEAP1-KD inAML#27. Figure 5e shows that KEAP1-KD
AML#27 is more resistant to daunorubicin compared with
NEG-KD. However, when we transfected AML#27 KEAP1-KD
cells with control miRNA, miR-125B antagomiR, miR-29B
mimic and miR-125B antagomiR in combination with
miR-29B mimic, only the combination decreased resistance
to daunorubicin (Figure 5f). These results demonstrate
that inhibiting miR-125B and overexpressing miR-29B in
combination increases apoptosis of primary AML and also
increases sensitivity of AML cells to current frontline
chemotherapy.
miR-29B and miR-125B gene targets in human AML.
Studies have shown that a number of different targets exist
for both miR-29B and miR-125B in AML (Supplementary
Table 3).18,20–28 Here we examine the expression of genes
listed in Supplementary Table 3 for their response to
transfection of control miRNA, miR-125B antagomiR,
miR-29B mimic and miR-125B antagomiR in combination
with miR-29B mimic. Figure 6a shows that MYBL2, AKT2,
CDK4 and SP1 are inhibited by miR-29B mimic in THP-1
cells; we also observe that AKT2 and CDK4 are further
inhibited by the addition of miR-125B antagomiR. From the
miR-125B targets, Figure 6a shows that MAPK14, STAT3 and
BAK1 show an increase in mRNA in response to miR-125B
antagomiR. Next, we examined the protein expression of
AKT2, STAT3 and BAK1. Figure 6b shows a reduction in
AKT2 protein expression in response to miR-29B mimic and
miR-125B antagomiR in combination with miR-29B mimic.
STAT3 showed a slight increase in response to miR-29B
mimic and miR-125B antagomiR in combination with
miR-29B mimic. BAK1 showed an increase in response to
miR-125B antagomir and miR-125B antagomiR in combina-
tion with miR-29B mimic.
Finally, we wanted to determine whether NRF2 deregulation
in AML affects miRNA levels to such an extent that expression
of their target genes is changed as a consequence. Figure 6c
shows a change in expression of AKT2, STAT3 and BAK1 but
not MCL1 mRNA in response to NRF2-KD or KEAP1-KD
compared with NEG-KD. Figure 6d shows changes in AKT2
and BAK1 protein expression in response to NRF2-KD and an
increase in response to KEAP1-KD. Together, these results
link the two major observations of this study; first, that NRF2
Table 1 AML patient sample information, NRF2 RNA expression and relative miR-125B1 and miR-29B1 RNA expression levels
Number Age Gender WHO diagnosis Cytogenetics % Blasts Fold NRF2 mRNA
over CD34+
Fold RNA over CD34+
miR-125B1 miR-29B1
AML#1 49 M AML with maturation Normal 80 3.35 6.57 0.04
AML#2 39 M AML with maturation Normal 65* 6.89 12.33 0.11
AML#3 64 M AML with RUNX1-RUNX1T1 t(8;21) 85 1.26 1.09 1.01
AML#4 92 F AML with myelodysplasia related changes Not available 70* 1.23 1.70 0.20
AML#5 82 F AML with MDSrelated changes Deletion 13 85 3.39 3.20 0.07
AML#6 46 F AML with maturation +4,+8, t(9;22) 70* 4.99 12.51 0.10
AML#7 66 F AML with maturation t(2;12) 65* 1.23 5.22 0.27
AML#8 78 M AML with MDS related changes Not available 85 4.19 9.85 0.01
AML#9 57 M AML without maturation Not available 95 4.35 4.59 0.09
AML#10 27 M AML with RUNX1-RUNX1T1 t(8;21) 60* 4.99 10.93 0.08
AML#11 25 M AML with maturation Normal 50* 4.81 6.63 0.37
AML#12 61 M Relapsed AML without maturation Not available 95 1.96 1.07 0.71
AML#13 28 F Acute Monoblastic and Monocytic Leukaemia Normal 90 4.68 6.52 0.33
AML#14 31 F AML without maturation Trisomy 8 75* 2.73 6.37 0.03
AML#15 84 M Acute meyloid leukaemia, NOS Not available 70* 3.99 2.43 0.24
AML#16 53 M AML with t(6;9)(p23;q34);DEK-NUP214 t(6;9) 65* 3.25 9.13 0.24
AML#17 51 F AML with maturation Normal 40* 4.54 3.45 0.02
AML#18 47 M Acute myeloid leukaemia without maturation Not available 90 4.20 2.07 1.33
AML#19 77 F AML with maturation Normal 70* 2.78 7.70 0.21
AML#20 62 M AML with maturation Complex 55* 2.96 2.67 0.59
AML#21 70 M AML with minimal differentiation Normal 95 2.01 1.98 0.64
AML#22 65 F AML with maturation Normal 40* 1.44 2.75 0.24
AML#23 77 M Therapy related AML Complex 70* 3.24 3.10 0.24
AML#24 40 F AML with minimal differentiation Normal 90 1.77 3.23 1.09
AML#25 70 M AML without maturation Complex 95 3.18 6.54 0.42
AML#26 91 F AML NOS Not available 75* 1.08 1.63 0.97
AML#27 59 F AMLwith t(8;21)(q22;q22); RUNX1-RUNX1T1 t(8;21) 85 1.17 1.44 0.53
This table defines the nature of the AML disease including WHO diagnosis and cytogenetics. NRF2, miR125B1 and miR-29B1 RNA expression levels over CD34+
control cells
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directly regulates miR-125B and miR-29B expression.
Second, that miR-125B and miR-29B synergistically influence
AML survival and chemoresistance, possibly via deregulation
of target genes such as AKT2, STAT3 or BAK1.
Discussion
Our understanding of the role of non-coding RNAmolecules in
diseases such as cancer is presently in its infancy. To date,
miRNAs have been shown to have a significant role in cancer
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Figure 6 miR-125B antagomiR and miR-29B mimic gene targets in AML cells. (a) THP-1 were transfected with control miRNA, miR-125B antagomiR (α125B), miR-29B
mimic (29B mimic) and miR-125B antagomiR in combination with miR-29B mimic for 48 h before cells were analysed for target gene expression using QRT-PCR. (b) THP-1 cells
were transfected with control miRNA, miR-125B antagomiR (α125B), miR-29B mimic (29B mimic) and miR-125B antagomiR in combination with miR-29B mimic for 48 h before
cells were analysed for AKT2, STAT3 and BAK1 using western blotting. Blots were reprobed for β-actin to show sample loading. (c) QRT-PCR of mRNA for AKT2, STAT3, BAK1
and MCL1 in THP-1 cells transduced with NEG-KD, NRF2-KD or KEAP1-KD. Values represent fold change in RNA expression over NEG-KD control. (d) THP-1 cells were
transduced with NEG-KD, NRF2-KD or KEAP1-KD before cells were analysed for AKT2, STAT3 and BAK1 protein expression using western blotting. Blots were reprobed for
β-actin to show sample loading. The numbers under the blots indicate densitometry analysis of the blots using Image J software, and the results are expressed as fold change
relative to the negative control
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biology through the regulation of both tumour suppressors and
oncogenes. Less is known, however, about the upstream
control of miRNA expression in cancer and the biological
processes that control miRNA expression. In AML, the
differential expression of a number of miRNAs has been
reported to be associated with the malignant phenotype but as
yet the upstream mechanisms by which this is controlled are
yet to be described.29–32 As we have previously identified
NRF2 as an important regulator of cell survival in AML, the aim
of the present study was to investigate the ability of NRF2 to
affect miRNA expression and furthermore define the function
of these miRNAs in human AML both in a resting state and in
response to front-line chemotherapeutic agents.
Through gene expression data and multiple transcription
factor binding assays, we found that NRF2 upregulates
mir-125B1 and downregulates miR-29B1 though binding to
specific ARE sites in the miR-125B1 and miR-29B1 regulatory
regions. Furthermore, we observed that by decreasing the
expression of miR-125B and increasing the expression of
miR-29B, the cells becomemore sensitive to apoptotic stimuli.
These findings are in keeping with previous observations that
miR-29B and miR-125B regulate the expression of multiple
survival pathways in AML. The global repression of miR-125B
targets and elevation of miR-29B targets genes would aid the
uncontrolled proliferative phenotype of AML. Therefore, in
Figures 6a and b, we analyse the targets of miR-29B and
miR-125B in AML cells transfected with corresponding mimic
and antagomir, both alone and in combination. We observe
changes in a number of genes including AKT2, CDK4,
MAPK14, STAT3, BCL2 and BAK1. Interestingly, AKT2 and
CDK4 are targets of miR-29B only; however, when we
co-transfect miR-125B antagomir and miR-29B mimic, we do
observe a further reduction over miR-29B mimic only. There
are no miR-125B sites within these two genes suggesting that
the combined observations are due to off-target effects.
Together, the cumulative repression of miR-29B and
the overexpression of miR-125B significantly contribute to
leukaemia cell proliferation within the bone marrow niche.
Transcription factors are generally structured in context of
networks. In AML, miR-29B downregulation has been found to
be associated with high C-MYC levels aswell as high SP1 and
NF-κB.33,34 Furthermore, NF-κB, JUN and C-MYC have been
linked to increased NRF2 activity in human cancer (including
AML)10,35 and NRF2 has been shown to transcriptionally
regulate miR-125B in kidney epithelia cells in response to
cisplatin-induced toxicity.36 Taken together, it is likely that
NRF2 has a central role in the complex network regulating
miR-29B and miR-125B in human AML.
We also highlight that other miRNAs may be regulated by
NRF2. The array data shown as Supplementary Table 1 show
that somemiRNAs are downregulated in response toNRF2-KD
and increased in response to sulforaphane. This list includes
miR-222, miR221, miR-223 miR-23a, miR-195 and miR-196a.
Of particular interest from this group is miR-222, miR-221 and
miR223, which have been shown to be highly expressed inAML
compared with other leukaemias.37 Moreover, we also noted
that high NRF2 activity caused a decrease in the expression of
miRNAs, which includes miR-154, miR146a and miR-181B. All
these miRNAs have been shown to be of interest in AML with
miR-146a being shown to have low expression in AML, which
correlates with high expression of its target gene CXCR4,38
which in a separate study has been shown to be regulated by
NRF2 in human HSC.39 Consequently in human AML, NRF2
not only regulates key genes involved in the reaction to
oxidative stress but also regulates miRNAs that appear to have
a broader impact on gene expression and regulation.
In summary, here we report the first description of upstream
miRNA regulation by NRF2 in a human cancer and its
downstream cyto-protective consequences. In doing so, we
not only provide novel mechanistic insight into the pro-
tumoural consequences of the constitutive NRF2 expression
in AML, but we also propose that targeting the NRF2
regulation of these miRNA (or the miRNA directly) would be
a biologically plausible therapeutic strategy to increase the
effectiveness of chemotherapy in human AML.
Materials and Methods
Materials. The AML-derived cell lines were obtained from the European
Collection of Cell Cultures where they are authenticated by DNA fingerprinting. In
the laboratory, they are used at low passage number for a maximum of 6 months
post-resuscitation, testing regularly for Mycoplasma infection. All primers were
purchased from Invitrogen (Paisley, UK). AKT2, STAT3 and BAK1 antibodies were
purchased from Cell Signalling Technology (Cambridge, MA, USA). NRF2 and
KEAP1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). All other reagents were obtained from Sigma-Aldrich (St. Louis, MO,
USA), unless indicated. To assess whether NRF2 regulates miRNA expression in
AML, we used commercially available OncomiR collection Cancer miRNA
qRT-PCR Array (SBI, Mountain View, CA, USA).
Primary AML cell culture. AML cells were obtained from patients' bone
marrow or blood following informed consent and under approval from the UK
National Research Ethics Service (LRECref07/H0310/146). For primary cell
isolation, heparinised blood was collected from volunteers and human peripheral
blood mononuclear cells isolated by Histopaque (Sigma-Aldrich, Dorset, UK) density
gradient centrifugation. AML samples that were less than 80% blasts were purified
using the CD34-positive selection kit (Miltenyi Biotec, Auburn, CA, USA) (denoted
by * in Table 1). Cell type was confirmed by microscopy and flow cytometry. We
obtained haematopoietic CD34+ cells from two sources, Stem Cell Technologies
(Manchester, UK) and volunteers. Positive selection of CD34+ cells were isolated
from peripheral blood mononuclear cells using a CD34-positive selection kit
(Miltenyi Biotec). For all CD34+ experiments, at least three different donors were
used to obtain the results presented in this paper. Cell type was confirmed by
microscopy and flow cytometry.
RNA extraction and real time PCR (RT-PCR). Total mRNA extraction
was carried out using mirVana miRNA isolation kit (Ambion, Paisley, UK) and
reverse transcribed using the miRscript II RT kit (Qiagen, Manchester, UK). All
mature miRNA were normalised to RNU6B and immature miRNA and mRNA were
normailsed to GAPDH for qRT-PCR as described previously.40 qRT-PCR was
carried out using SYBR green technology (Qiagen). The samples were preamplified
at 95 °C for 2 min, after which was amplified for 45 cycles at 95 °C for 15 s, 60 °C
for 10 s and 72 °C for 10 s. The qRT-PCR was performed on the LightCycler480
(Roche, Burgess Hill, UK).
Virus construction and infection. Lentiviruses containing miRNA
sequence miRNA-Nrf2 (5′-TTAATGAGTTCACTGTCAACT-3′), miRNA-KEAP1
(5′-GTTTTGGCCACTGACTGAC-3′) and miR-NEG were constructed and
produced as described previously.41 For transduction, THP-1 cells and AML
blasts cells were plated onto 12-well plates (5 × 104 cells/well) and infected with
lentiviruses (multiplicity of infection of 15) with 8 μg/ml Polybrene (Sigma, Dorset,
UK). Transduced cells were analyzed by flow cytometry (Accuri, BD Biosciences,
Oxford, UK), real-time PCR (Roche) and western blotting.
Transfections. AML transfections were carried out with 2 × 106 cells using the
Amaxa Nucleofactor Kit II (Cambridge, UK). Control miR, miR-29B mimic and
miR-125B antagomiR, control siRNA, KEAP1 and NRF2 siRNA were purchased
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from Invitrogen were transfected in at a concentration of 45 nm. For control miR, the
miR-mimic negative control and the anti-miR miRNA inhibitor negative control for
single experiments and combined miR-mimic negative control and the anti-miR
miRNA inhibitor negative control in combined experiments were used. For all gene
expression experiments, the cells were incubated for 24 h post transfection before
RNA extraction. For the cell viability assays, AML cells were incubated for 48 h post
transfection. For reporter assays, 0.5 μg of PGL4 reporter and pRL-TK control
constructs were co-transfected into THP-1. Transfected cells were incubated for 24 h
before the indicated treatments. For reporter assay, cells were treated with Dual-
Luciferase reporter assay system (Promega, Southampton, UK).
Western blotting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and western blot analyses were performed as described previously. Briefly, whole
cell lysates as well as nuclear and cytosolic were extracted and sodium dodecyl
sulfate-polyacrylamide gel electrophoresis separation was performed.42 Protein was
transferred to nitrocellulose and western blot analysis performed with the indicated
antisera according to their manufacturer’s guidelines.
Cloning of miR-125B promoter construct. To generate the p125B
promoter construct containing ARE3, a DNA fragment containing 2.6 kb of the
human 125b promoter region was amplified from genomic DNA with PCR
and specific primers: 5′-TGAGAGGAGCGCAACAATG-3′ reverse primer and
5′-AGAAAGGCCACCAAGATTCAC-3′ forward primer. The fragment was cloned
into the PGL4.11 basic plasmid (Promega). To generate mutated NRF2 construct
(p125B NRF2 MUT) the sense PCR primer used was 5′-GCTGTG
GCTGtTTTGTtATTCTCTTTGACTAG-3′. This mutation was introduced with the
QuikChange XL Site-Directed Mutagenesis Kit (Agilent, Stockport, UK).
Cell viability and apoptosis assays. THP-1, Kasumi-1, primary CD34+
HSC and primary AML cells were transfected with control miR (miR-mimic negative
control and the anti-miR miRNA inhibitor negative control for single experiments and
combined miR-mimic negative control and the anti-miR miRNA inhibitor negative
control in combined experiments), miR-29B mimic and miR-125B antagomiR and
combined miR-29B mimic and miR-125B antagomiR for 24 h. THP-1 cells were
analysed for apoptosis using PI/Annexin V staining. THP-1, Kasumi-1, primary
CD34+ HSC and primary AML transfected cells were treated with different
concentrations of chemotherapy agents and incubated for 48 h; then, viable cells
were measured with Cell-Titre GLO (Promega).
Chromatin immunoprecipitation assay. THP-1 cells were transfected
with control siRNA or KEAP1 siRNA 24 h before the cells were fixed with 1%
formaldehyde in medium for 10 min at room temperature. The sonication conditions
were optimised to determine generation of DNA fragments between 300 and 600
base pairs in length. Chromatin was immunoprecipitated with IgG, anti-NRF2
(Cell Signalling). The association of NRF2 was measured by RT-PCR on
immunoprecipitated chromatin using primers spanning the ARE sites described in
Figure 3a and Supplementary Table 4.
Statistical analyses. Student’s t test was performed to assess statistical
significance from controls. Results with Po0.05 were considered statistically
significant (*). Results represent the mean± S.D. of three independent experiments.
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